Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT02733042 |
Title | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001) |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase Ib/II |
Variant Requirements | No |
Sponsors | Celgene Corporation |
Indications | |
Therapies |
Durvalumab + Lenalidomide + Rituximab |
Age Groups: | adult |
Covered Countries | USA | ITA | FRA | DEU |